Evidence map›Paper›PMID 38020312›Full record

ReviewImmunotherapy advances2023

Human infection challenge in the pandemic era and beyond, HIC-Vac annual meeting report, 2022.

Megan V C Barnes, Anika Mandla, Emma Smith, Maija Maskuniitty, Peter J M Openshaw, HIC-Vac meeting contributors

Abstract readReview
In one paragraph

Review in Immunotherapy advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Megan V C BarnesNational Heart and Lung Institute, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-5474-3262
Anika MandlaNational Heart and Lung Institute, Imperial College London, London, UK.
Emma SmithDepartment of Infectious Disease, Imperial College London, London, UK.
Maija MaskuniittyNational Heart and Lung Institute, Imperial College London, London, UK.
Peter J M OpenshawNational Heart and Lung Institute, Imperial College London, London, UK.
HIC-Vac meeting contributors

Funding

Medical Research Council MC_PC_17220Medical Research Council MR/Y033736/1Wellcome Trust
6 · The paper itself

Abstract

HIC-Vac is an international network of researchers dedicated to developing human infection challenge studies to accelerate vaccine development against pathogens of high global impact. The HIC-Vac Annual Meeting (3rd and 4th November 2022) brought together stakeholders including researchers, ethicists, volunteers, policymakers, industry partners, and funders with a strong representation from low- and middle-income countries. The network enables sharing of research findings, especially in endemic regions. Discussions included pandemic preparedness and the role of human challenge to accelerate vaccine development during outbreak, with industry speakers emphasising the great utility of human challenge in vaccine development. Public consent, engagement, and participation in human challenge studies were addressed, along with the role of embedded social science and empirical studies to uncover social, ethical, and regulatory issues around human infection challenge studies. Study volunteers shared their experiences and motivations for participating in studies. This report summarises completed and ongoing human challenge studies across a variety of pathogens and demographics, and addresses other key issues discussed at the meeting.

Indexed as

controlled human infection modelsexperimental medicineinfectious diseaselow-middle-income countriesmucosal immunologyvaccination

Identifiers

PMID38020312
PMCPMC10640868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.